Moving Toward Personalized Medicine in Rheumatoid Arthritis: Snps in Methotrexate Intracellular Pathways are Associated with Methotrexate Therapeutic Outcome

References

• Gervasini G , BenitezJ , CarrilloJA . Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy . Eur. J. Clin. Pharmacol.66 ( 8 ), 755 – 774 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Haga SB , BurkeW . Using pharmacogenetics to improve drug safety and efficacy . JAMA291 ( 23 ), 2869 – 2871 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Klareskog L , Van Der HeijdeD , De JagerJPet al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial . Lancet363 ( 9410 ), 675 – 681 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Lima A , MonteiroJ , BernardesMet al. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms . Biomed. Res. Int.2014 , 368681 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Smith HS , SmithAR , SeidnerP . Painful rheumatoid arthritis . Pain Physician14 ( 5 ), E427 – E458 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Benucci M , SaviolaG , ManfrediMet al. Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature . Int. J. Rheumatol.2011 , 845496 ( 2011 ).
   PubMedGoogle Scholar
• Weinblatt ME , KaplanH , GermainBFet al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study . Arthritis Rheum.37 ( 10 ), 1492 – 1498 ( 1994 ).
   PubMedGoogle Scholar
• Kremer JM . Toward a better understanding of methotrexate . Arthritis Rheum.50 ( 5 ), 1370 – 1382 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Romao VC , LimaA , BernardesMet al. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? Immunol. Res. 60 ( 2 ), 289 – 310 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Romao VC , CanhaoH , FonsecaJE . Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?BMC Med.11 ( 17 ), 1 – 24 ( 2013 ).
   PubMedGoogle Scholar
• Lima A , SousaH , MonteiroJ , AzevedoRet al. Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers . Pharmacogenomics15 ( 12 ), 1611 – 1635 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zhu H , DengFY , MoXBet al. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update . Pharmacogenomics15 ( 4 ), 551 – 566 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lima A , BernardesM , SousaHet al. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients . Pharmacogenomics15 ( 6 ), 807 – 820 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tian H , CronsteinBN . Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis . Bull. NYU Hosp. Jt. Dis.65 ( 3 ), 168 – 173 ( 2007 ).
   PubMedGoogle Scholar
• Swierkot J , SzechinskiJ . Methotrexate in rheumatoid arthritis . Pharmacol. Rep.58 ( 4 ), 473 – 492 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Chan ES , CronsteinBN . Molecular action of methotrexate in inflammatory diseases . Arthritis Res.4 ( 4 ), 266 – 273 ( 2002 ).
   PubMedGoogle Scholar
• Lima A , AzevedoR , SousaHet al. Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics . Pharmacogenomics14 ( 11 ), 1337 – 1351 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Inoue K , YuasaH . Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy . Drug Metab. Pharmacokinet.29 ( 1 ), 12 – 19 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dervieux T , GreensteinN , KremerJ . Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis . Arthritis Rheum.54 ( 10 ), 3095 – 3103 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Dalrymple JM , StampLK , O’donnellJLet al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis . Arthritis Rheum.58 ( 11 ), 3299 – 3308 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lloyd HG , DeussenA , WuppermannHet al. The transmethylation pathway as a source for adenosine in the isolated guinea-pig heart . Biochem. J.252 ( 2 ), 489 – 494 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Palmer JL , AbelesRH . The mechanism of action of S-adenosylhomocysteinase . J. Biol. Chem.254 ( 4 ), 1217 – 1226 ( 1979 ).
   PubMed Web of Science ®Google Scholar
• Adam T . Purine de novo synthesis-mechanisms and clinical implications . Klin. Biochem. Metab.13 ( 34 ), 177 – 181 ( 2005 ).
   Google Scholar
• Jackson EK , DubeyRK . Role of the extracellular cAMP-adenosine pathway in renal physiology . Am. J. Physiol. Renal Physiol.281 ( 4 ), F597 – F612 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Lloyd HG , SchraderJ . Adenosine metabolism in the guinea pig heart: the role of cytosolic S-adenosyl-L-homocysteine hydrolase, 5′-nucleotidase and adenosine kinase . Eur. Heart. J.14 ( Suppl. I ), 27 – 33 ( 1993 ).
   PubMedGoogle Scholar
• Schrader J , HaddyFJ , GerlachE . Release of adenosine, inosine and hypoxanthine from the isolated guinea pig heart during hypoxia, flow-autoregulation and reactive hyperemia . Pflugers Arch.369 ( 1 ), 1 – 6 ( 1977 ).
   PubMed Web of Science ®Google Scholar
• Schwiebert EM , KishoreBK . Extracellular nucleotide signaling along the renal epithelium . Am. J. Physiol. Renal Physiol.280 ( 6 ), F945 – F963 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Cutolo M , SulliA , PizzorniCet al. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis . Ann. Rheum. Dis.60 ( 8 ), 729 – 735 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Riksen NP , BarreraP , Van Den BroekPHet al. Methotrexate modulates the kinetics of adenosine in humans in vivo . Ann. Rheum. Dis.65 ( 4 ), 465 – 470 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Montesinos MC , DesaiA , DelanoDet al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68 . Arthritis Rheum.48 ( 1 ), 240 – 247 ( 2003 ).
   PubMedGoogle Scholar
• Cronstein BN . Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis . Pharmacol. Rev.57 ( 2 ), 163 – 172 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Lima A , BernardesM , AzevedoRet al. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in portuguese rheumatoid arthritis patients . Toxicol. Sci.142 ( 1 ), 196 – 209 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lima A , SeabraV , BernardesMet al. Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients . PLoS ONE9 ( 10 ), e108165 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lima A , BernardesM , AzevedoRet al. Pharmacogenomics of methotrexate membrane transport pathway: can clinical response to methotrexate in rheumatoid arthritis be predicted? Int. J. Mol. Sci. 16 ( 6 ), 13760 – 13780 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Aletaha D , NeogiT , SilmanAJet al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative . Ann. Rheum. Dis.69 ( 9 ), 1580 – 1588 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Prevoo ML , Van’T HofMAet al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis . Arthritis Rheum.38 ( 1 ), 44 – 48 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 ( 2010 ). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf .
   Google Scholar
• Dervieux T , FurstD , LeinDOet al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis . Arthritis Rheum.50 ( 9 ), 2766 – 2774 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Wessels JA , KooloosWM , De JongeRet al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis . Arthritis Rheum.54 ( 9 ), 2830 – 2839 ( 2006 ).
   PubMedGoogle Scholar
• James HM , GillisD , HissariaPet al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis . J. Rheumatol.35 ( 4 ), 562 – 571 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Sharma S , DasM , KumarAet al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians . Pharmacogenet. Genomics19 ( 10 ), 823 – 828 ( 2009 ).
   PubMedGoogle Scholar
• Stamp LK , ChapmanPT , O’DonnellJLet al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate . Pharmacogenet. Genomics20 ( 6 ), 367 – 376 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Grabar PB , RojkoS , LogarDet al. Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway . Ann. Rheum. Dis.69 ( 5 ), 931 – 932 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Fransen J , KooloosWM , WesselsJAet al. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure . Pharmacogenomics13 ( 9 ), 1087 – 1094 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kato T , HamadaA , MoriSet al. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis . Drug Metab. Pharmacokinet.27 ( 2 ), 192 – 199 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Owen SA , HiderSL , MartinPet al. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients . Pharmacogenomics J.13 ( 3 ), 227 – 234 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lee YC , CuiJ , CostenbaderKHet al. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate . Rheumatology (Oxford)48 ( 6 ), 613 – 617 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Watson MA , StewartRK , SmithGBet al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution . Carcinogenesis19 ( 2 ), 275 – 280 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Bradic M , CostaJ , CheloIM . Genotyping with sequenom . Methods Mol. Biol.772 , 193 – 210 ( 2011 ).
   PubMedGoogle Scholar
• Sole X , GuinoE , VallsJet al. SNPStats: a web tool for the analysis of association studies . Bioinformatics22 ( 15 ), 1928 – 1929 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Halilova KI , BrownEE , MorganSLet al. Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int. J. Rheumatol. 2012 , 978396 ( 2012 ).
   PubMedGoogle Scholar
• Ronnelid J , WickMC , LampaJet al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression . Ann. Rheum. Dis.64 ( 12 ), 1744 – 1749 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Morel J , CombeB . How to predict prognosis in early rheumatoid arthritis . Best Pract. Res. Clin. Rheumatol.19 ( 1 ), 137 – 146 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Anderson JJ , WellsG , VerhoevenACet al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration . Arthritis Rheum.43 ( 1 ), 22 – 29 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Schoonjans F , ZalataA , DepuydtCEet al. MedCalc: a new computer program for medical statistics . Comput. Methods Programs Biomed.48 ( 3 ), 257 – 262 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Xu H , GuanY . Detecting local haplotype sharing and haplotype association . Genetics197 ( 3 ), 823 – 838 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Davis LA , PolkB , MannAet al. Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis . Clin. Exp. Rheumatol.32 ( 3 ), 324 – 332 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hayashi H , FujimakiC , DaimonTet al. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis . J. Clin. Pharm. Ther.34 ( 3 ), 355 – 361 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Swierkot J , SlezakR , KarpinskiPet al. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR, TYMS and TCII and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis . Pol. Arch. Med. Wewn.125 ( 3 ), 152 – 61 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Van Ede AE , LaanRF , BlomHJet al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity . Semin. Arthritis Rheum.27 ( 5 ), 277 – 292 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Stamp LK , RobertsRL . Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases . Pharmacogenomics12 ( 10 ), 1449 – 1463 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Van Der Put NM , GabreelsF , StevensEMet al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet. 62 ( 5 ), 1044 – 1051 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Xiao H , XuJ , ZhouXet al. Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis . Clin. Exp. Rheumatol.28 ( 5 ), 728 – 733 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wessels JA , De Vries-BouwstraJK , HeijmansBTet al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes . Arthritis Rheum.54 ( 4 ), 1087 – 1095 ( 2006 ).
   PubMedGoogle Scholar
• Soukup T , DosedelM , PavekPet al. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients . Rheumatol. Int.35 ( 7 ), 1149 – 1161 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Saleh MM , IrshaidYM , MustafaKN . Methylene tetrahydrofolate reductase genotypes frequencies: association with the toxicity of and response to methotrexate in rheumatoid arthritis patients . Int. J. Clin. Pharmacol. Ther.53 ( 2 ), 154 – 162 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Taraborelli M , AndreoliL , ArchettiSet al. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients . Clin. Exp. Rheumatol.27 ( 3 ), 499 – 502 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Caliz R , Del AmoJ , BalsaAet al. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population . Scand. J. Rheumatol.41 ( 1 ), 10 – 14 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Plaza-Plaza JC , AguileraM , Canadas-GarreMet al. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis . OMICS16 ( 11 ), 589 – 595 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Owen SA , LuntM , BowesJet al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms . Pharmacogenomics J.13 ( 2 ), 137 – 147 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Choe JY , LeeH , JungHY , ParkSH , BaeSC , KimSK . Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis . Rheumatol. Int.32 ( 6 ), 1837 – 1842 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mena JP , Salazar-ParamoM , Gonzalez-LopezLet al. Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases . Pharmacogenomics J.11 ( 4 ), 287 – 291 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bohanec Grabar P , LogarD , LestanBet al. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism . Eur. J. Clin. Pharmacol.64 ( 11 ), 1057 – 1068 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Frosst P , BlomHJ , MilosRet al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase . Nat. Genet.10 ( 1 ), 111 – 113 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Fenech M . The role of folic acid and vitamin B12 in genomic stability of human cells . Mutat. Res.475 ( 1 ), 57 – 67 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Wettergren Y , OdinE , CarlssonGet al. MTHFR, MTR, and MTRR polymorphisms in relation to p16INK4A hypermethylation in mucosa of patients with colorectal cancer . Mol. Med.16 ( 9 ), 425 – 432 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Matsuo K , SuzukiR , HamajimaNet al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma . Blood97 ( 10 ), 3205 – 3209 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Olteanu H , MunsonT , BanerjeeR . Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase . Biochemistry41 ( 45 ), 13378 – 13385 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Salazar J , MoyaP , AltesAet al. Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients? Pharmacogenomics 15 ( 8 ), 1079 – 1090 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Weisman MH , FurstDE , ParkGSet al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis . Arthritis Rheum.54 ( 2 ), 607 – 612 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Hider SL , ThomsonW , MackLF , ArmstrongDJet al. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX . Rheumatology (Oxford)47 ( 8 ), 1156 – 1159 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Morisaki T , GrossM , MorisakiHet al. Molecular basis of AMP deaminase deficiency in skeletal muscle . Proc. Natl. Acad. Sci. USA89 ( 14 ), 6457 – 6461 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Wessels JA , Van Der KooijSM , Le CessieSet al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis . Arthritis Rheum.56 ( 6 ), 1765 – 1775 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Morinobu S , MorinobuA , KanagawaSet al. Glutathione S-transferase gene polymorphisms in Japanese patients with rheumatoid arthritis . Clin. Exp. Rheumatol.24 ( 3 ), 268 – 273 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Mattey DL , HassellAB , PlantMet al. Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope . Ann. Rheum. Dis.58 ( 3 ), 164 – 168 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Rindfleisch JA , MullerD . Diagnosis and management of rheumatoid arthritis . Am. Fam. Physician72 ( 6 ), 1037 – 1047 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Gibofsky A . Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis . Am. J. Manag. Care18 ( Suppl. 13 ), S295 – S302 ( 2012 ).
   PubMedGoogle Scholar
• Moncrieffe H , HinksA , UrsuSet al. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype . Pharmacogenet. Genomics20 ( 11 ), 665 – 676 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• De Rotte MC , BulatovicM , HeijstekMWet al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis . J. Rheumatol.39 ( 10 ), 2032 – 2040 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bohanec Grabar P , Leandro-GarciaLJ , Inglada-PerezLet al. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients . Pharmacogenomics13 ( 14 ), 1583 – 1594 ( 2012 ).
   PubMed Web of Science ®Google Scholar